VAERS Explorer
Back to explore

Report #2898453

Received Jun 1, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
—
Recovered
Not recovered
Vaccinated
May 25, 2026
Onset
May 1, 2026
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2——

Symptoms (1)

Headache

Symptom narrative

have a splitting headache; This non-serious case was reported by a consumer via call center representative and described the occurrence of headache in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 25-MAY-2026, the patient received the 2nd dose of Shingrix. In MAY-2026, less than a week after receiving Shingrix, the patient experienced headache (Verbatim: have a splitting headache). The outcome of the headache was not resolved. It was unknown if the reporter considered the headache to be related to Shingrix. Additional Information: GSK Receipt Date:26-MAY-2026 The patient got Shingrix vaccination before the day of reporting and had a persistent headache and enquiring if she could take Ibuprofen for headache. The batch number was not provided upon follow up with the reporter.